- A post hoc (after the end of trial) analysis of the Phase 3 ANCHOR study showed treatment with Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) lowered potential artery plaque-forming lipid and inflammatory markers in patients with chronic kidney disease (CKD). The data were presented at the American Heart Association 2017 Scientific Sessions in Anaheim, CA.
- The company says Vascepa exhibited the treatment benefit without elevating "bad" cholesterol (LDL-C) and with a safety profile similar to placebo in 35 CKD patients.
- CKD patients with persistent high triglycerides despite treatment with statins have a high risk of developing cardiovascular disease.
- The ongoing large-scale cardiovascular disease outcomes study, REDUCE-IT, will include some CKD patients.
- Shares are up 6% premarket on light volume.